Compare SOLAI Limited (SLAI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs GeneDx Holdings Corp — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: GeneDx Holdings Corp is far larger — about 154.6× SOLAI Limited's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| SLAI | WGS | |
|---|---|---|
Market Cap | $16.69M | $2.58B |
Sector | Technology | Technology |
52-Week High | $21.63 | $167.51 |
52-Week Low | $2.74 | $34.51 |
Enterprise Value | $16.33M | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price change. The stock shows a bullish technical signal from moving averages and oscillators, but faces severe fundamental challenges including negative gross and net income margins, a net loss of $33.88 million in 2025, and a delisting notice from the NYSE. A 7:1 reverse stock split is planned for July 2026 to address listing requirements.
The outlook is highly speculative. While low P/S and P/B ratios suggest potential value, persistent losses and delisting risks overshadow any upside. The single analyst coverage rates it Hold, reflecting extreme caution. Investment carries high risk of capital loss given operational deficits and exchange status uncertainty.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
